Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer
June 23 2020 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
commercial-stage biopharmaceutical company focused on developing
and commercializing innovative therapies for people with rare
debilitating, chronic neuromuscular and neurological diseases,
today announced the promotion of Jeffrey Del Carmen to Chief
Commercial Officer, effective today. Mr. Del Carmen joined Catalyst
in August of 2018 as Senior Vice President of Sales and Marketing.
In his new role, Mr. Del Carmen will report to the CEO of Catalyst
and will serve on Catalyst's Executive Leadership Team.
Catalyst also announced that Pete Curry, Sr. has
been promoted to Vice President of Sales (from his current position
as Catalyst's National Sales Director) and that Maria Pandolfo has
been promoted to Vice President of Patient Services. Both will
continue to report to Mr. Del Carmen in his new role as Catalyst's
Chief Commercial Officer.
“Jeff has proven his ability by leading the
sales and marketing team that successfully launched Firdapse® for
the treatment of adult LEMS patients in the United States,” said
Patrick J. McEnany Chairman and CEO of Catalyst. “With Jeff’s
leadership and experience, Catalyst is well-positioned for
sustained success as we continue to expand access to Firdapse to
the LEMS community, as well as prepare for a potential launch of
Firdapse for the treatment of patients suffering from anti-MuSK
antibody positive myasthenia gravis ("MuSK-MG)."
Mr. McEnany added, “On behalf of the Company, I
would like to thank Dan Brennan for his leadership and significant
contributions over the past two years and wish him success as he
pursues his next opportunity.”
“During the past two years, Catalyst has made
tremendous progress in establishing a commercial organization that
has rapidly provided access to Firdapse for many LEMS patients
across the United States, and I am excited to build on the launch
momentum as we continue to bring this important medication to LEMS
patients and hopefully to patients who will benefit from the use of
Firdapse for the treatment of other rare neuromuscular conditions,”
said Jeff Del Carmen.
Mr. Del Carmen has more than 23 years of
experience in pharmaceutical sales and product management. Just
prior to joining Catalyst, Mr. Del Carmen served as VP of Business
Development at Paragon Biosciences, evaluating commercial assets to
expand Paragon’s portfolio. Previously, Mr. Del Carmen was Senior
Director-Rare Disease Marketing at Marathon Pharmaceuticals. Prior
to joining Marathon, Mr. Del Carmen briefly served as Vice
President of Sales at Insys Therapeutics. From 2011 to 2016, Mr.
Del Carmen was with Lundbeck (US), with the last two years as
Movement Disorder-National Sales Director. Prior to joining
Lundbeck, Mr. Del Carmen spent 16 years at Abbott Laboratories in
various sales and marketing leadership roles with increasing
responsibility. Mr. Del Carmen received a B.A degree in Economics
from the University of Dayton and an MBA degree from the University
of Wisconsin.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, including Lambert-Eaton
myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia
gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3.
Catalyst's new drug application for Firdapse® (amifampridine) 10 mg
tablets for the treatment of adults with LEMS was approved in
November 2018 by the U.S. Food & Drug
Administration ("FDA"), and Firdapse is now commercially
available in the United States. Prior to its approval,
Firdapse for LEMS had received breakthrough therapy designation and
orphan drug designation from the FDA.
Firdapse is currently being evaluated in
clinical trials for the treatment of MuSK-MG and SMA Type 3 and has
received Orphan Drug Designation from the FDA for
myasthenia gravis.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including (i) the impact of the effects of the
COVID-19 pandemic on Catalyst's 2020 net product revenues and on
the timeline for reporting the top-line results from Catalyst's
MuSK-MG trial and SMA Type 3 proof-of-concept study, (ii) whether
Firdapse will ever be approved for use as a treatment for any other
disease, including MuSK-MG, and (iii) those factors described in
Catalyst's Annual Report on Form 10-K for the fiscal year 2019 and
Catalyst's other filings with the U.S. Securities and Exchange
Commission (SEC), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024